Targeting chronic inflammation to prevent age-related disease progression
Learn more
WHO WE ARE
Introduction to LifeCyte
LifeCyte is advancing next-generation treatments designed to slow the progression of degenerative diseases. By focusing on inflammation at the cellular level, our approach offers new possibilities for patients facing vision loss, cognitive decline, and other age-related challenges.
PRIMARY FOCUS
A leading cause of vision loss in older adults, AMD damages the retina and blurs central vision.
LifeCyte's clinical studies are evaluating the effect on inflamation and drusen build up. Decreasing inflamation and drusen build up are associated with slowing disease progreasssion and visual loss.
SECONDARY FOCUS
MCI is an early stage of memory decline that often leads to dementia. LifeCyte’s clinical studies are evaluating the effect on brain inflammation to slow disease progression and cognitive decline.
SECONDARY FOCUS
Alzheimer’s causes memory loss and toxic protein buildup in the brain. LifeCyte’s product is designed to calm inflammatory pathways linked to this damage, aiming to reduce Amyloid burden and protect cognitive function.
SECONDARY FOCUS
Head trauma can trigger swelling and chronic brain inflammation. LifeCyte’s therapy is designed to reduce those inflammatory signals and support recovery.
LifeCyte's novel formulation is applicable to multiple chronic inflammatory conditions, with potential for broader therapeutic applications across age-related diseases, including arthritis.
LIFECYTE'S PROTOTYPE PRODUCT
A New Approach
to AMD
RestoViz is LifeCyte’s primary, initial product offering - an innovative oral combination therapy that represents a new approach to age-related macular degeneration.
RestoViz™
Unlike the current standard of care that only manages symptoms, RestoViz™ targets the factors that lead to disease progression, including inflammation, oxidative stress, poor blood flow, and toxic protein buildup in the brain and eyes.
WHAT RESTOVIZ DOES
Sustains Healthy Visual Function
Helps Maintain a Healthy Retina & Macula
Protects from Inflammation and Oxidative Stress
Promotes Cellular Health Within The Eye
PRELIMINARY
CLINICAL STUDY RESULTS
Reduced drusen buildup
Slowed disease progression
Prolonged visual activity
Sustains independent lifestyle
ADVANTAGES FOR PATIENTS
Easy to take
Daily dose oral supplement
Well tolerated
Zero serious adverse events
No ARIA risk
No brain swelling/bleeding like some FDA-approved Alzheimer’s drugs
Multiple Targets
Inflammation + oxidative stress + amyloid
BEHIND THE INNOVATION
Ken Brown
CEO & Co-Founder
Ken is proven operator and serial entrepreneur, he led the transformation and successful exit of a multi-generational family business while simultaneously founding, scaling, and negotiating the sale of an industry related software company. His dualtrack leadership demonstrates a rare ability to execute across both traditional and technology-driven sectors. With deep expertise in growth strategy, operational excellence, and value creation, he has consistently built high-performing teams and delivered strong returns for stakeholders.
Mike Moorhead
CFO & Co-Founder
Mike is an entrepreneur experienced in building and exiting successful businesses. He cofounded a company that developed an innovative product, achieved large scale national distribution in major retailers, and led it to a successful exit. With CFO experience, he has a strong background in strategic growth and financial management, thriving at the intersection of innovation and disciplined leadership.
Howard Rosing, MD, PHD
Chief Medical Officer
Howard is a board-certified neurologist and physician-inventor with 40+ years of experience. He founded and exited multiple medical endeavors, serves as CEO/CMO of Global Biomedical Technologies (co-inventor of Comfort Release® technology), and is Chief Medical Officer at LifeCyte Innovations leading clinical trials in AMD, MCI, and TBI.
Kenn Adach
Chief Marketing & Sales Officer
Kenn Adach is a strategic marketing leader who has created value for leading brands including Bausch & Lomb, Playtex, Unilever, and Sherwin Williams. At Bausch & Lomb, he reinvigorated a $150MM OTC pharmaceutical portfolio (PreserVision®/AREDS2), achieving a 25% sales increase through strategic repositioning. He has driven innovation creating 50+ new products and holds a B.S. from University of South Carolina and MBA from Rutgers. At LifeCyte Innovations, he serves as Chief Marketing & Sales Officer.
Max Pfahler
Director of Clinical Research
Max is a clinical researcher with 8+ years of experience in translational research targeting AMD, glaucoma, and Alzheimer's disease. As Clinical Trials Manager at University of Illinois and Director of Clinical Research at LifeCyte Innovations, he has led FDA-compliant trials, written successful IND applications, and managed 15+ IRB approved studies.
LEARN MORE